{"created":"2023-07-27T06:29:26.326740+00:00","id":14227,"links":{},"metadata":{"_buckets":{"deposit":"64830054-8866-4022-9777-bdf6d26103a7"},"_deposit":{"created_by":3,"id":"14227","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"14227"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00014227","sets":["1132:1133:1134"]},"author_link":["24451","234","24452","260","24453","71"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2006-01-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"83","bibliographicPageStart":"80","bibliographicVolumeNumber":"97","bibliographic_titles":[{"bibliographic_title":"Cancer Science"}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"We describe an immunocompetent 19-year-old man with CD20-positive primary central nervous system (CNS) lymphoma refractory to chemotherapy and irradiation. After intraventricular administration of rituximab, a chimeric anti-CD20 monoclonal antibody, supplemented with autologous serum, a remarkable response developed to the CNS parenchymal lymphoma. Cytotoxicity assays showed that untreated patient's serum with rituximab, but not that of heat-inactivated patient's serum with rituximab or rituximab alone, induced potent rituximab-mediated cytotoxicity against tumor cells in the patient's cerebrospinal fluid, suggesting induction of complement-dependent cytotoxicity against CNS lymphoma. © 2006 Japanese Cancer Association.","subitem_description_type":"Abstract"}]},"item_4_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"医薬保健研究域医学系","subitem_description_type":"Other"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Japanese Cancer Association / Blackwell Publishing Ltd"}]},"item_4_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1111/j.1349-7006.2006.00138.x","subitem_relation_type_select":"DOI"}}]},"item_4_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.jca.gr.jp/","subitem_relation_type_select":"URI"}}]},"item_4_rights_23":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© Japanese Cancer Association 日本癌学会"}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AA11808050","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1347-9032","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Takami, Akiyoshi"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Hayashi, Akiyoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kita, Daisuke"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Nishimura, Ryosei"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Asakura, Hidesaku"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"Nakao, Shinji"}],"nameIdentifiers":[{},{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-03"}],"displaytype":"detail","filename":"ME-PR-NAKAO-S-80.pdf","filesize":[{"value":"189.4 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ME-PR-NAKAO-S-80.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/14227/files/ME-PR-NAKAO-S-80.pdf"},"version_id":"37f0f740-4229-4538-9182-072ef1131e1d"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab"}]},"item_type_id":"4","owner":"3","path":["1134"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-03"},"publish_date":"2017-10-03","publish_status":"0","recid":"14227","relation_version_is_last":true,"title":["Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-07-28T00:50:50.634702+00:00"}